Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[99mTc]Tc-DB8 SPECT Imaging in Prostate and Breast Cancer
NCT05940298Phase 1Completed
- Sponsor
- Tomsk National Research Medical Centre of the Russian Academy of Sciences
- Start
- Jul 2023
- Primary completion
- Jun 2024
- Modality
- Alpha Emitters, Beta Emitters
- Countries
- 1
01
Overview
Phase 1, open-label trial of [99mTc]Tc-DB8 in prostate cancer (PCa) and breast cancer (2 arms), sponsored by Tomsk National Research Medical Centre of the Russian Academy of Sciences. Primary endpoints: Gamma camera-based whole-body [99mTc]Tc-DB8 uptake value at 24 hours, SPECT-based [99mTc]Tc-DB8 value in tumor lesions at 6 hours and 2 more. Started Jul 2023; status: completed.
02
Drugs
[99mTc]Tc-DB8
03
Conditions
prostate cancer (PCa)breast cancer
Beyond the preview
Go deeper on NCT05940298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05940298.